Docetaxel side chain 143527-70-2 98%min HPLC 130kgs in stocks 6 years of production experience

Name:Docetaxel side chain

CAS Number:143527-70-2Name:3,5-Oxazolidinedicarboxylicacid, 2,2-dimethyl-4-phenyl-, 3-(1,1-dimethylethyl) ester, (4S,5R)-Superlist Name:(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acidFormula:C17H23NO5Molecular Structure:Synonyms:3,5-Oxazolidinedicarboxylicacid, 2,2-dimethyl-4-phenyl-, 3-(1,1-dimethylethyl) ester, (4S-trans)-;(4S,5R)-5-Carboxy-2,2-dimethyl-4-phenyl-3-(tert-butoxycarbonyl)oxazolidine;(4S,5R)-N-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylicacid;(4S,5R)-N-(tert-butoxycarbonyl)-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylic acid;(4S-trans)-2,2-Dimethyl-4-phenyl-3,5-oxazolidinedicarboxylic acid 3-(1,1-dimethylethyl) ester;Molecular Weight:321.37Density:1.178 g/cm3Boiling Point:459.009 °C at 760 mmHgFlash Point:231.4 °CAppearance:off-white semi solid

Formula structure:

Function:

Taxotere as a single agent was compared to mitomycin C in combination with vinblastine and showed a one-year survival rate of 49 percent among breast cancer patients, compared to 33 percent for those treated with the combination therapy. Fifty percent more patients treated with Taxotere were alive one year after therapy, compared to those treated with the combination. Median time to progression and time to treatment failure were significantly longer for Taxotere. The overall response rate among patients treated with Taxotere was 28 percent vs. the combination’s 9.5 percent.